Waypoint Bio raises $20.0M (China, May 2026)
Find the investors funding Health rounds
326,000+ verified VCs, angels and family offices — direct emails, check sizes and stage filters.
Exclusive: Waypoint Bio raises $20M to run three CAR-T trials in China - Endpoints News
Waypoint Bio is a biotechnology company focused on developing innovative CAR-T therapies. The company aims to address unmet medical needs in cancer treatment through its clinical trials in China. This funding will support the execution of three CAR-T trials, highlighting the company's commitment to advancing cancer therapies.
Exclusive: Waypoint Bio raises $20M to run three CAR-T trials in China Endpoints News
| Aug 24, 2026 | Xpeng | $900.0M | Series A | China |
| Aug 24, 2026 | XPENG Robotics | $900.0M | — | China |
| Aug 24, 2026 | OriginFlow | $70.0M | — | China |
| Aug 18, 2026 | Xinyang Micro | $1.6M | Angel | China |
11,288 investors back startups in China
You just read who funded Waypoint Bio. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 5 investor contact unlocks a month, no card required.